2023 Fiscal Year Final Research Report
Screening and Functional Analysis of Biomarkers Useful for Differentiating Between IPF and Non-IPF ILD
Project/Area Number |
21K06947
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Review Section |
Basic Section 49030:Experimental pathology-related
|
Research Institution | Hamamatsu University School of Medicine |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
目黒 史織 浜松医科大学, 医学部, 助教 (40724290)
|
Project Period (FY) |
2021-04-01 – 2024-03-31
|
Keywords | 間質性肺疾患 / 特発性肺線維症 / 筋線維芽細胞 / 線維芽細胞 |
Outline of Final Research Achievements |
Interstitial lung disease (ILD) can be classified into idiopathic pulmonary fibrosis (IPF) and non-IPF-ILD from a treatment perspective, but it can be challenging to differentiate between IPF and non-IPF-ILD. The applicants conducted a comparison of gene profiling between myofibroblasts in mouse bleomycin-induced pulmonary fibrosis and normal lung fibroblasts, finding that serum levels of GREM1 were significantly higher in the IPF patient group, followed by the non-IPF-ILD patient group, and the healthy control group. The area under the ROC curve for IPF versus non-IPF-ILDs was 0.759, which was superior to the three commonly used serum markers (KL6, SP-D, LDH) in clinical practice.
|
Free Research Field |
実験病理学
|
Academic Significance and Societal Importance of the Research Achievements |
間質性肺疾患(ILD)は、多様な疾患群である。ILDの中で、予後不良である特発性肺線維症(IPF)に対しては抗線維化薬を用いた治療が行われているのに対し、非IPF-ILDに対しては、主に免疫抑制療法が行われている。このように、IPFと非IPF-ILDに対する治療法は大きく異なるので、IPFと非IPF-ILDを正確に診断することは極めて重要である。このような背景から、IPFと非IPF-ILDとの鑑別診断に有用な非侵襲的な血清バイオマーカーであるGREM1の発見は学術的および社会的に意義があると思われる。
|